Table 3

Univariable and multivariable analyses of association between echocardiographic variables and cancer-therapy-related cardiac dysfunction

Univariable analysisMultivariable analysis
HR (95% CI)P valueModel 1Model 2Model 3
HR (95% CI)P valueHR (95% CI)P valueHR (95% CI)P value
Age, years0.99 (0.94 to 1.04)0.610.96 (0.89–1.03)0.260.99 (0.93–1.06)0.790.99 (0.93–1.06)0.82
Female1.15 (0.26 to 5.02)0.86
Cancer type (breast cancer)0.38 (0.08 to 1.92)0.240.18 (0.03–1.10)0.063
Anthracycline type (doxorubicin)1.07 (0.25 to 4.49)0.931.22 (0.27–5.43)0.80
Cumulative anthracycline dose (per 10 mg/m2 increase)0.99 (0.89 to 1.10)0.891.00 (0.87–1.14)0.95
Baseline echocardiogram
LVEDV, mL0.99 (0.96 to 1.03)0.99
LVESV, mL1.00 (0.93 to 1.06)0.91
LVEF, %0.85 (0.69 to 1.04)0.11
LAVi, mL/m2 1.00 (0.92 to 1.09)0.94
E, cm/s0.99 (0.95 to 1.03)0.65
A, cm/s0.99 (0.95 to 1.03)0.62
E/A ratio0.84 (0.13 to 5.62)0.86
e', cm/s1.23 (0.91 to 1.65)0.18
a', cm/s0.93 (0.67 to 1.29)0.66
E/e' ratio0.76 (0.48 to 1.21)0.25
TRV, m/s0.81 (0.11 to 5.86)0.84
TAPSE, mm0.92 (0.71 to 1.20)0.54
GLSTb0.89 (0.65 to 1.21)0.45
T10.80 (0.59 to 1.08)0.14
Δ0.97 (0.91 to 1.04)0.42
Apical-LSTb0.96 (0.81 to 1.13)0.60
T10.98 (0.83 to 1.15)0.76
Δ1.01 (0.97 to 1.04)0.80
Mid-LSTb0.92 (0.68 to 1.23)0.55
T10.87 (0.64 to 1.18)0.38
Δ0.99 (0.94 to 1.05)0.78
Basal-LSTb0.91 (0.68 to 1.22)0.52
T10.60 (0.43 to 0.83)0.002
Δ0.91 (0.84 to 0.99)0.0260.90 (0.83–0.97)0.0090.91 (0.83–0.99)0.0210.91 (0.83–0.99)0.025
  • A, peak atrial diastolic wave velocity; a', peak atrial systolic mitral annular velocity; e', peak early diastolic mitral annular velocity; E, peak early diastolic wave velocity; GLS, global longitudinal strain; LAVi, left atrial volume index; LS, longitudinal strain; LVEDV, left ventricular end diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end systolic volume; TAPSE, tricuspid annular plane systolic excursion; TRV, tricuspid regurgitation velocity.